Sionna Therapeutics(SION)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SION Sionna Therapeutics

休市中 09-18 16:00:00 EDT

5.96

-1.22

-16.99%

盘后6.04

+0.08+1.34%

19:49 EDT

最高7.19	最低5.90	成交量370.48万
今开7.12	昨收7.18	日振幅17.97%
总市值2.68亿	流通市值9,968万	总股本4,500万
成交额2,277万	换手率22.15%	流通股本1,673万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SION","market":"US","secType":"STK","nameCN":"Sionna Therapeutics","latestPrice":5.96,"timestamp":1789761600000,"preClose":7.18,"halted":0,"volume":3704779,"hourTrading":{"tag":"盘后","latestPrice":6.04,"preClose":5.96,"latestTime":"19:49 EDT","volume":52578,"amount":315849.4854,"timestamp":1789775397071,"change":0.08,"changeRate":0.013423,"amplitude":0.017315},"delay":0,"changeRate":-0.16991643454038993,"floatShares":16725500,"shares":44998073,"eps":-2.16827,"marketStatus":"休市中","change":-1.22,"latestTime":"09-18 16:00:00 EDT","open":7.12,"high":7.19,"low":5.9,"amount":22771168.493749,"amplitude":0.179666,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.16827,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"listingDate":1738904400000,"exchange":"NASDAQ","adjPreClose":7.18,"preHourTrading":{"tag":"盘前","latestPrice":7.34,"preClose":7.18,"latestTime":"09:29 EDT","volume":5058,"amount":37214.745858,"timestamp":1789738153842,"change":0.16,"changeRate":0.022284,"amplitude":0.063705},"postHourTrading":{"tag":"盘后","latestPrice":6.04,"preClose":5.96,"latestTime":"19:49 EDT","volume":52578,"amount":315849.4854,"timestamp":1789775397071,"change":0.08,"changeRate":0.013423,"amplitude":0.017315},"volumeRatio":2.219932649117784,"impliedVol":1.9187,"impliedVolPercentile":0.8062},"requestUrl":"/m/hq/s/SION","defaultTab":"news","newsList":[{"id":"1187547745","title":"Sionna Therapeutics董事会批准裁员约46%并推行成本节约措施","url":"https://stock-news.laohu8.com/highlight/detail?id=1187547745","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187547745?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:04","pubTimestamp":1789416280,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics宣布，其董事会已正式批准一项重大重组计划，将裁减约46%的员工队伍，并同步实施一系列成本节约举措。此举标志着该公司在当前市场环境下主动调整运营策略，以优化资源配置并应对财务挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183463983","title":"Sionna Therapeutics宣布推进Sion-451与Sion-2222双重组合疗法进入2a期概念验证试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1183463983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183463983?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:02","pubTimestamp":1789416129,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics今日宣布，计划将其研发中的Sion-451与Sion-2222双重组合疗法推进至2a期概念验证临床试验阶段。这一决定标志着该公司在相关治疗领域迈出了关键性的一步。此次推进的双重组合方案，旨在通过两种药物的协同作用，为患者提供更具潜力的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143232434","title":"Sionna Therapeutics 获 RBC 上调评级至“行业表现”，目标价却从23美元大幅下调至5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143232434","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143232434?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:59","pubTimestamp":1786373949,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics 迎来评级上调的“好消息”，却伴随着目标价的大幅削减。RBC 资本市场宣布，将该股评级从“落后大盘”上调至“行业表现”。然而，目标价却从23美元骤降至5美元——这一调整幅度之大，令人瞩目。评级上调或许反映了对公司前景的某种乐观，但目标价的大幅缩水，也暗示了其中隐含的风险与不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183280522","title":"Tenax与Sionna股价暴跌：临床试验双双失利","url":"https://stock-news.laohu8.com/highlight/detail?id=1183280522","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183280522?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:54","pubTimestamp":1786373686,"startTime":"0","endTime":"0","summary":"周一，生物科技公司Tenax Therapeutics与Sionna Therapeutics的股价遭遇重创，原因在于两家公司先后公布了各自后期临床试验失败的噩耗。Tenax的股价暴跌近90%，其一款针对心力衰竭的实验性药物，在III期临床试验中未能帮助患者行走距离超过安慰剂组。该试验以六分钟步行距离作为标准测试指标——这正是心力衰竭治疗领域的常规衡量标准。此外，另一项评估患者自报症状的试验目标也未能达标。然而，Sionna公司表示，将不再继续推进该药物作为辅助治疗的研发工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TENX","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147797605","title":"Sionna Therapeutics公布囊性纤维化两项开发项目顶线数据，并发布公司最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1147797605","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147797605?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:01","pubTimestamp":1786359672,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics（Sionna Therapeutics）正式披露了其在囊性纤维化领域两项开发项目的顶线数据，同时同步更新了公司整体运营状况。这些数据为相关项目提供了关键性临床参考，并进一步明确了公司未来的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134160903","title":"Sionna Therapeutics 旗下 Sion-719 二期a试验未达主要终点，该联合用药项目宣告终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1134160903","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134160903?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:01","pubTimestamp":1786359670,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics 宣布，其 Sion-719 在二期a阶段临床试验中遭遇重大挫折——未能触及关键疗效终点。鉴于此，公司决定终止该药物作为附加疗法的研发项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138373042","title":"Sionna Therapeutics 维持2.899亿美元现金储备，预计运营资金可支撑至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1138373042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138373042?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:24","pubTimestamp":1778585042,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics 公司宣布，其现金及现金等价物储备稳固保持在2.899亿美元。基于当前运营计划与财务预测，公司管理层预计，现有资金足以支持其各项研发及企业活动持续进行至2028年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150814177","title":"Sionna Therapeutics完成精准CF二期a阶段试验入组，评估Nbd1稳定剂Sion-719联合标准疗法对囊性纤维化患者疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1150814177","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150814177?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287782,"startTime":"0","endTime":"0","summary":"生物制药公司Sionna Therapeutics宣布，其针对囊性纤维化治疗的精准CF二期a阶段临床试验已完成患者入组。该试验重点评估在标准疗法基础上加用Nbd1稳定剂Sion-719的疗效与安全性。\n作为针对囊性纤维化根本病因的创新疗法，Sion-719通过稳定CFTR蛋白的Nbd1结构域发挥作用。此次试验采用精准医疗策略，旨在为特定患者群体探索更有效的治疗方案。\n临床试验的顺利推进标志着Sionna Therapeutics在呼吸系统疾病治疗领域取得重要进展。公司将持续关注试验数据，为后续研发决策提供科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517602818","title":"Sionna Therapeutics(SION.US)获Stifel首次覆盖，给予买入评级, 目标价32.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602818","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517602818?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:42","pubTimestamp":1741110163,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics(SION.US)获Stifel首次覆盖，给予买入评级, 目标价32.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05014248524159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SION","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177801026","title":"异动解读 | Sionna Therapeutics盘中大涨38.89%,开盘即大涨33%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1177801026","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177801026?lang=zh_cn&edition=full","pubTime":"2025-02-08 02:02","pubTimestamp":1738951356,"startTime":"0","endTime":"0","summary":"生物技术公司Sionna Therapeutics今日盘中股价大涨38.89%,引发市场高度关注。\n\n公司今日在纳斯达克交易所成功 IPO,首次公开募股规模扩大至1.91亿美元,发行价为每股18美元。然而当日开盘后,Sionna Therapeutics的股价即飙升至24美元,较发行价飙升33%,充分体现了资本市场对公司的热捧。\n\n作为一家从事治疗囊性纤维化疾病药物研发的生物技术公司,Sionna Therapeutics正在与制药业巨头Vertex公司展开激烈竞争,力图在这一快速增长的市场占据一席之地。分析人士认为,Sionna成功 IPO体现了投资者对其长期前景的高度认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Sionna Therapeutics盘中大涨38.89%,开盘即大涨33%创新高","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sionnatx.com","stockEarnings":[{"period":"1week","weight":-0.2408},{"period":"1month","weight":-0.0464},{"period":"3month","weight":-0.8402},{"period":"6month","weight":-0.8362},{"period":"1year","weight":-0.7434},{"period":"ytd","weight":-0.8551}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sionna Therapeutics, Inc.于2019年8月根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，其使命是通过开发使囊性纤维化跨膜电导调节蛋白功能正常化的新药，为CF患者提供具有临床意义的益处，从而彻底改变目前囊性纤维化患者的治疗模式。","exchange":"NASDAQ","name":"Sionna Therapeutics","nameEN":"Sionna Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sionna Therapeutics(SION)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sionna Therapeutics(SION)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sionna Therapeutics,SION,Sionna Therapeutics股票,Sionna Therapeutics股票老虎,Sionna Therapeutics股票老虎国际,Sionna Therapeutics行情,Sionna Therapeutics股票行情,Sionna Therapeutics股价,Sionna Therapeutics股市,Sionna Therapeutics股票价格,Sionna Therapeutics股票交易,Sionna Therapeutics股票购买,Sionna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sionna Therapeutics(SION)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sionna Therapeutics(SION)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}